Overview

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Tesaro, Inc.
Treatments:
Niraparib